Linker Information

Linker Information

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)

Citation

Visitor Map

Correspondence

General Information of This Linker

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

QD6/B09-AZ1508 [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 40 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1035B)
Experiment 2 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST551C)
Experiment 3 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1328)
Experiment 4 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST2081)
Experiment 5 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1749)
Experiment 6 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST751)
Experiment 7 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST935B)
Experiment 8 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST551)
Experiment 9 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1506)
Experiment 10 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST374)
Experiment 11 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST599)
Experiment 12 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1976B)
Experiment 13 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST115)
Experiment 14 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1092)
Experiment 15 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST2495)
Experiment 16 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1885)
Experiment 17 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1989)
Experiment 18 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1092B)
Experiment 19 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%-20%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST2891)
Experiment 20 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.94% (Day 32)
Method Description	To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (1 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
In Vivo Model	Pancreatic PDX model (PDX: MEDI-PANC-08)
Experiment 21 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 4.50% (Day 32)
Method Description	To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (2 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
In Vivo Model	Pancreatic PDX model (PDX: MEDI-PANC-08)
Experiment 22 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST396)
Experiment 23 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1684)
Experiment 24 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1151)
Experiment 25 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST379)
Experiment 26 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1437)
Experiment 27 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%-40%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1104B)
Experiment 28 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 35.86% (Day 32)
Method Description	To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (3 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
In Vivo Model	Pancreatic PDX model (PDX: MEDI-PANC-08)
Experiment 29 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40%-60%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1035)
Experiment 30 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST2822B)
Experiment 31 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1271)
Experiment 32 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST698B)
Experiment 33 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60%-80%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1229)
Experiment 34 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60%-80%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1906)
Experiment 35 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60%-80%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST742)
Experiment 36 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60%-80%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1243)
Experiment 37 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST140)
Experiment 38 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST137)
Experiment 39 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST1976C)
Experiment 40 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00%
Method Description	When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm³), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: ST2869)

Revealed Based on the Cell Line Data

Click To Hide/Show 24 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	0.00%	Negative EGFR expression (EGFR ++); Negative MET expression (MET -)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	5.00%	Low EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H23 cells		CVCL_1547
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	12.00%	Moderate EGFR expression (EGFR ++); Low MET expression (MET +)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung carcinoma	A-427 cells		CVCL_1055
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	29.00%	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	45.00%	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	54.00%	High EGFR expression (EGFR +++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenosquamous carcinoma	NCI-H596 cells		CVCL_1571
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	65.00%	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	66.00%	High EGFR expression (EGFR +++); High MET expression (MET +++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	HCC827-GR-step cells		CVCL_S705
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	79.00%	High EGFR expression (EGFR +++); High MET expression (MET +++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	79.00%	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1792 cells		CVCL_1495
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	33.00 pM	High EGFR expression (EGFR +++); High MET expression (MET +++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	HCC827-GR-step cells		CVCL_S705
Experiment 13 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	81.00 pM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1792 cells		CVCL_1495
Experiment 14 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	91.00 pM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 15 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	96.00 pM	High EGFR expression (EGFR +++); High MET expression (MET +++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 16 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 17 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 0.17 nM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 18 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 19 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.27 nM	High EGFR expression (EGFR +++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenosquamous carcinoma	NCI-H596 cells		CVCL_1571
Experiment 20 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.48 nM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++);
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay. In the representative experiment, pre-treatment of NCI-H1975 cells with MET IgG RAA22.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 21 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.96 nM	Moderate EGFR expression (EGFR ++); Low MET expression (MET +)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung carcinoma	A-427 cells		CVCL_1055
Experiment 22 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.50 nM	Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++);
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay. In the representative experiment, pre-treatment of NCI-H1975 cells with MET IgG B09.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 23 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 60.00 nM	Low EGFR expression (EGFR ++); Moderate MET expression (MET ++)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung adenocarcinoma	NCI-H23 cells		CVCL_1547
Experiment 24 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 60.00 nM	Negative EGFR expression (EGFR ++); Negative MET expression (MET -)
Method Description	The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577

References

Ref 1	Antibody molecules and conjugates; 2023-05-19.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Linker Name

QD6/B09-AZ1508

Linker Type

Thiol-sensitive linker

Antibody-Linker Relation